Spoken Alpha
JAZZ
Jazz Pharmaceuticals plc
Overview
Jazz Pharmaceuticals plc is a Healthcare company operating in Biotechnology with a $14.12B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0514 Q&A exchanges
- Q4 FY2025Earnings2026-02-2511 Q&A exchanges
- Q3 FY2025Earnings2025-11-0517 Q&A exchanges
- Q2 FY2025Earnings2025-08-0618 Q&A exchanges
- Q1 FY2025Earnings2025-05-0617 Q&A exchanges
- Q4 FY2024Earnings2025-02-2514 Q&A exchanges
- Q3 FY2024Earnings2024-11-0614 Q&A exchanges
- Q2 FY2024Earnings2024-07-3116 Q&A exchanges
- Q1 FY2024Earnings2024-05-0114 Q&A exchanges
- Q4 FY2023Earnings2024-02-2817 Q&A exchanges
- Q3 FY2023Earnings2023-11-0815 Q&A exchanges
- Q2 FY2023Earnings2023-08-0913 Q&A exchanges
- Q1 FY2023Earnings2023-05-1016 Q&A exchanges
- Q4 FY2022Earnings2023-03-0115 Q&A exchanges
- Q3 FY2022Earnings2022-11-0921 Q&A exchanges
- Q2 FY2022Earnings2022-08-0312 Q&A exchanges
- Q1 FY2022Earnings2022-05-0517 Q&A exchanges
- Q4 FY2021Earnings2022-03-0114 Q&A exchanges
- Q3 FY2021Earnings2021-11-0918 Q&A exchanges
- Q2 FY2021Earnings2021-08-0328 Q&A exchanges
- Q1 FY2021Earnings2021-05-0415 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $5.06—Rev— vs ——EODHD
- Q1 FY20262026-05-05EPS$6.34 vs $4.66+36.2%Rev$1.07B vs ——EODHD
- Q4 FY20252026-02-24EPS$6.64 vs $6.51+2.1%Rev$1.20B vs ——EODHD
- Q3 FY20252025-11-04EPS$8.13 vs $5.96+36.4%Rev$1.13B vs ——EODHD
- Q2 FY20252025-08-04EPS$-8.25 vs $-7.62-8.3%Rev$1.05B vs ——EODHD
- Q1 FY20252025-05-06EPS$-1.52 vs $4.81-100.0%Rev$897.8M vs ——EODHD
- Q4 FY20242025-02-24EPS$6.60 vs $5.81+13.6%Rev$1.09B vs ——EODHD
- Q3 FY20242024-11-05EPS$6.61 vs $5.50+20.2%Rev$1.05B vs ——EODHD
- Q2 FY20242024-07-30EPS$5.30 vs $4.77+11.1%Rev$1.02B vs ——EODHD
- Q1 FY20242024-04-30EPS$2.68 vs $4.18-35.9%Rev$902.0M vs ——EODHD
- Q4 FY20232024-02-27EPS$5.02 vs $5.18-3.1%Rev$1.01B vs ——EODHD
- Q3 FY20232023-11-07EPS$4.84 vs $4.93-1.8%Rev$972.1M vs ——EODHD
- Q2 FY20232023-08-08EPS$4.51 vs $4.43+1.8%Rev$957.3M vs ——EODHD
- Q1 FY20232023-05-09EPS$3.95 vs $4.24-6.8%Rev$892.8M vs ——EODHD
- Q4 FY20222023-02-28EPS$-0.07 vs $0.32-100.0%Rev$972.1M vs ——EODHD
- Q3 FY20222022-11-08EPS$5.17 vs $4.66+10.9%Rev$940.7M vs ——EODHD
- Q2 FY20222022-08-02EPS$4.30 vs $4.19+2.6%Rev$932.9M vs ——EODHD
- Q1 FY20222022-05-03EPS$3.73 vs $3.84-2.9%Rev$813.7M vs ——EODHD
- Q4 FY20212022-02-28EPS$4.21 vs $3.64+15.7%Rev$896.7M vs ——EODHD
- Q3 FY20212021-11-08EPS$4.20 vs $3.32+26.5%Rev$838.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $5.06 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $6.34 | $4.66 | +36.2% | $1.07B | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $6.64 | $6.51 | +2.1% | $1.20B | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $8.13 | $5.96 | +36.4% | $1.13B | — | — | EODHD |
| Q2 FY2025 | 2025-08-04 | $-8.25 | $-7.62 | -8.3% | $1.05B | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-1.52 | $4.81 | -100.0% | $897.8M | — | — | EODHD |
| Q4 FY2024 | 2025-02-24 | $6.60 | $5.81 | +13.6% | $1.09B | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $6.61 | $5.50 | +20.2% | $1.05B | — | — | EODHD |
| Q2 FY2024 | 2024-07-30 | $5.30 | $4.77 | +11.1% | $1.02B | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $2.68 | $4.18 | -35.9% | $902.0M | — | — | EODHD |
| Q4 FY2023 | 2024-02-27 | $5.02 | $5.18 | -3.1% | $1.01B | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $4.84 | $4.93 | -1.8% | $972.1M | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $4.51 | $4.43 | +1.8% | $957.3M | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $3.95 | $4.24 | -6.8% | $892.8M | — | — | EODHD |
| Q4 FY2022 | 2023-02-28 | $-0.07 | $0.32 | -100.0% | $972.1M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $5.17 | $4.66 | +10.9% | $940.7M | — | — | EODHD |
| Q2 FY2022 | 2022-08-02 | $4.30 | $4.19 | +2.6% | $932.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-03 | $3.73 | $3.84 | -2.9% | $813.7M | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $4.21 | $3.64 | +15.7% | $896.7M | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $4.20 | $3.32 | +26.5% | $838.1M | — | — | EODHD |
Source: EODHD. JAZZ reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks JAZZ's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.93 | $3.13 | +25.5% | +2.6% | +4.9% |
| Q4 FY2026 | $3.68 | $3.03 | +21.6% | -4.5% | -7.4% |
| Q3 FY2026 | $4.17 | $3.26 | +27.9% | -1.0% | -0.9% |
| Q2 FY2026 | $3.54 | $3.06 | +15.7% | -3.0% | -3.3% |
| Q1 FY2025 | $3.72 | $3.25 | +14.6% | +4.7% | +2.2% |
| Q4 FY2025 | $4.02 | $3.36 | +19.5% | +5.1% | +7.2% |
| Q3 FY2025 | $4.05 | $3.37 | +20.2% | -3.7% | -1.9% |
| Q2 FY2025 | $3.93 | $3.21 | +22.5% | +0.5% | +3.1% |
| Q1 FY2024 | $4.16 | $3.38 | +23.0% | -5.6% | -7.9% |
| Q4 FY2024 | $3.94 | $3.34 | +18.0% | -5.1% | -5.6% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Renee D GalaCEO6 mo10 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last call held guidance Q2 FY2026
- Philip L JohnsonCFO4 mo9 callsCurrentSample
CFO since 2026 • 2/2 beats (100%) • last guidance raise Q2 FY2026
- Neena M PatilEVP & Chief Legal Officer5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • guidance suspended Q3 FY2026
- Samantha PearceEVP, Chief Commercial Officer5 mo3 callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance cut Q2 FY2026
- Patricia CarrSVP, Chief Accounting Officer7 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • guidance suspended Q2 FY2026
- Robert IannoneEVP, Global Head of R&D & CMO7 mo21 callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance cut Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for JAZZ.
$ curl https://api.spokenalpha.com/v1/companies/JAZZFAQ
Frequently asked about JAZZ
Where can I find Jazz Pharmaceuticals plc's (JAZZ) earnings call transcripts?
Spoken Alpha indexes JAZZ's earnings call transcripts at https://spokenalpha.com/companies/JAZZ. Each call links to attributed speakers and parsed analyst Q&A.
When was Jazz Pharmaceuticals plc's most recent earnings call?
Jazz Pharmaceuticals plc (JAZZ) held its most recent earnings call on 2026-05-05, covering fiscal Q1 2026.
What sector is JAZZ in?
Jazz Pharmaceuticals plc (JAZZ) operates in the Healthcare sector (Biotechnology industry).